文献速递血栓与止血

内脏静脉血栓形成的抗凝治疗:系统综述与荟萃分析

Anticoagulant therapy for splanchnic vein thrombosis: a systematic review and meta-analysis.
PubMed 文献 · Blood · 2021-01-01

该系统综述与荟萃分析检索了MEDLINE、EMBASE和clinicaltrials.gov从建库至2019年12月的文献,纳入97项研究共7969例内脏静脉血栓形成(SVT)患者,评估抗凝治疗的有效性与安全性。抗凝治疗组SVT再通率58%、血栓进展5%、复发性静脉血栓栓塞症(VTE)11%、大出血9%、总死亡率11%;未抗凝组分别为22%、15%、14%、16%、25%。与未治疗相比,抗凝治疗再通率更高(RR 2.39),血栓进展(RR 0.24)、大出血(RR 0.73)和总死亡率(RR 0.45)更低。

要点

  • 抗凝治疗组SVT再通率为58%,未抗凝组为22%,抗凝组再通率更高(RR 2.39)。
  • 抗凝治疗组血栓进展5%、大出血9%、总死亡率11%,均低于未抗凝组。
  • 接受抗凝治疗的患者复发性VTE发生率仍达11%,各亚组间效应一致。

核心结论

  • 抗凝治疗可提高SVT再通率并降低血栓进展风险,且不增加大出血。
  • 接受抗凝治疗的患者复发性VTE发生率仍较高。
  • 效应在不同患者亚组中一致。

研究设计与样本

  • 系统综述与荟萃分析,检索MEDLINE、EMBASE和clinicaltrials.gov从建库至2019年12月,无语言限制。
  • 纳入报告SVT患者影像学或临床结局的观察性研究和随机对照试验。
  • 共识别4312条记录,最终分析97项研究、7969例患者。
  • 采用随机效应模型计算合并比例和风险比(RR)及95%置信区间(CI)。
  • 该试验在PROSPERO数据库注册,注册号为CRD42019127870。

主要发现

  • 抗凝治疗组SVT再通率58%(95% CI 51-64),未抗凝组22%(95% CI 15-31)。
  • 抗凝治疗组SVT进展5%(95% CI 3-7),未抗凝组15%(95% CI 8-27)。
  • 抗凝治疗组复发性VTE 11%(95% CI 8-15),未抗凝组14%(95% CI 9-21)。
  • 抗凝治疗组大出血9%(95% CI 7-12),未抗凝组16%(95% CI 13-20)。
  • 抗凝治疗组总死亡率11%(95% CI 9-14),未抗凝组25%(95% CI 20-31)。

关键数值与推荐

  • 与未治疗相比,抗凝治疗再通率更高(RR 2.39;95% CI 1.66-3.44)。
  • 与未治疗相比,抗凝治疗血栓进展更低(RR 0.24;95% CI 0.13-0.42)。
  • 与未治疗相比,抗凝治疗大出血更低(RR 0.73;95% CI 0.58-0.92)。
  • 与未治疗相比,抗凝治疗总死亡率更低(RR 0.45;95% CI 0.33-0.60)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Treatment of splanchnic vein thrombosis (SVT) is challenging, and evidence to guide therapeutic decisions remains scarce. The objective of this systematic review and meta-analysis was to determine the efficacy and safety of anticoagulant therapy for SVT. MEDLINE, EMBASE, and clinicaltrials.gov were searched from inception through December 2019, without language restrictions, to include observational studies and randomized controlled trials reporting radiological or clinical outcomes in patients with SVT. Pooled proportions and risk ratios (RRs) with 95% confidence intervals (CIs) were calculated in a random-effects model. Of 4312 records identified by the search, 97 studies including 7969 patients were analyzed. In patients receiving anticoagulation, the rates of SVT recanalization, SVT progression, recurrent venous thromboembolism (VTE), major bleeding, and overall mortality were 58% (95% CI, 51-64), 5% (95% CI, 3-7), 11% (95% CI, 8-15), 9% (95% CI, 7-12), and 11% (95% CI, 9-14), respectively. The corresponding values in patients without anticoagulation were 22% (95% CI, 15-31), 15% (95% CI, 8-27), 14% (95% CI, 9-21), 16% (95% CI, 13-20), and 25% (95% CI, 20-31). Compared with no treatment, anticoagulant therapy obtained higher recanalization (RR, 2.39; 95% CI, 1.66-3.44) and lower thrombosis progression (RR, 0.24; 95% CI, 0.13-0.42), major bleeding (RR, 0.73; 95% CI, 0.58-0.92), and overall mortality (RR, 0.45; 95% CI, 0.33-0.60). These results demonstrate that anticoagulant therapy improves SVT recanalization and reduces the risk of thrombosis progression without increasing major bleeding. The incidence of recurrent VTE remained substantial in patients receiving anticoagulation, as well. Effects were consistent across the different subgroups of patients. This trial was registered on the PROPERO database at (https://www.crd.york.ac.uk/prospero//display_record.php?ID=CRD42019127870) as #CRD42019127870.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Valeriani E, Di Nisio M, Riva N, et al. Anticoagulant therapy for splanchnic vein thrombosis: a systematic review and meta-analysis. Blood. 2021. PMID: 32911539. doi:10.1182/blood.2020006827

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。